Recent UK type 2 diabetes treatment guidance represents a near whole population indication for SGLT2-inhibitor therapy
View ORCID ProfileKatherine G Young, Rhian Hopkins, View ORCID ProfileBeverley M Shields, View ORCID ProfileNicholas J Thomas, View ORCID ProfileAndrew P McGovern, View ORCID ProfileJohn M Dennis
doi: https://doi.org/10.1101/2023.08.04.23293666
Katherine G Young
1University of Exeter Medical School. Address: Department of Clinical and Biomedical Sciences, RILD Building, Royal Devon & Exeter Hospital, Barrack Road, Exeter EX2 5DW, UK
Rhian Hopkins
1University of Exeter Medical School. Address: Department of Clinical and Biomedical Sciences, RILD Building, Royal Devon & Exeter Hospital, Barrack Road, Exeter EX2 5DW, UK
Beverley M Shields
1University of Exeter Medical School. Address: Department of Clinical and Biomedical Sciences, RILD Building, Royal Devon & Exeter Hospital, Barrack Road, Exeter EX2 5DW, UK
Nicholas J Thomas
1University of Exeter Medical School. Address: Department of Clinical and Biomedical Sciences, RILD Building, Royal Devon & Exeter Hospital, Barrack Road, Exeter EX2 5DW, UK
Andrew P McGovern
1University of Exeter Medical School. Address: Department of Clinical and Biomedical Sciences, RILD Building, Royal Devon & Exeter Hospital, Barrack Road, Exeter EX2 5DW, UK
John M Dennis
1University of Exeter Medical School. Address: Department of Clinical and Biomedical Sciences, RILD Building, Royal Devon & Exeter Hospital, Barrack Road, Exeter EX2 5DW, UK
![Loading Loading](https://www.medrxiv.org/sites/all/modules/contrib/panels_ajax_tab/images/loading.gif)
Data Availability
CPRD data are available by application, subject to protocol approval through CPRD's Research Data Governance (RDG) Process.
Posted August 08, 2023.
Recent UK type 2 diabetes treatment guidance represents a near whole population indication for SGLT2-inhibitor therapy
Katherine G Young, Rhian Hopkins, Beverley M Shields, Nicholas J Thomas, Andrew P McGovern, John M Dennis
medRxiv 2023.08.04.23293666; doi: https://doi.org/10.1101/2023.08.04.23293666
Recent UK type 2 diabetes treatment guidance represents a near whole population indication for SGLT2-inhibitor therapy
Katherine G Young, Rhian Hopkins, Beverley M Shields, Nicholas J Thomas, Andrew P McGovern, John M Dennis
medRxiv 2023.08.04.23293666; doi: https://doi.org/10.1101/2023.08.04.23293666
Subject Areas
- Addiction Medicine (336)
- Allergy and Immunology (664)
- Anesthesia (178)
- Cardiovascular Medicine (2599)
- Dermatology (218)
- Emergency Medicine (391)
- Epidemiology (12134)
- Forensic Medicine (10)
- Gastroenterology (752)
- Genetic and Genomic Medicine (4031)
- Geriatric Medicine (379)
- Health Economics (670)
- Health Informatics (2605)
- Health Policy (994)
- Hematology (359)
- HIV/AIDS (832)
- Medical Education (397)
- Medical Ethics (109)
- Nephrology (426)
- Neurology (3797)
- Nursing (208)
- Nutrition (564)
- Oncology (1989)
- Ophthalmology (576)
- Orthopedics (235)
- Otolaryngology (303)
- Pain Medicine (249)
- Palliative Medicine (72)
- Pathology (470)
- Pediatrics (1098)
- Primary Care Research (443)
- Public and Global Health (6470)
- Radiology and Imaging (1379)
- Respiratory Medicine (866)
- Rheumatology (395)
- Sports Medicine (337)
- Surgery (438)
- Toxicology (51)
- Transplantation (185)
- Urology (165)